A Two-Part Study Investigating the Relative Bioavailability and the Potential Food Effect After a Single Oral Dose Administration of a New Formulation of SYT-510, and the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Oral Dose Administration of SYT-510 in Healthy Subjects
Latest Information Update: 04 Nov 2025
At a glance
- Drugs SYT 510 (Primary)
- Indications Anxiety disorders; Mood disorders; Traumatic stress disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Synendos Therapeutics
Most Recent Events
- 24 Sep 2025 Results published in the Synendos Therapeutics Media Release
- 05 Nov 2024 New trial record